Acute Lymphoblastic Leukemia: The Current and Future State of Care
A panel made up of expert hematologists Ryan Cassaday, MD, Armin Ghobadi, MD, Elias Jabbour, MD, and Gary J. Schiller, MD discusses current standards-of-care in Acute Lymphoblastic Leukemia as well as key data presented at the American Society of Hematology’s 2022 Annual Meeting.
EP. 1: Patient Presentation and Diagnosis in Acute Lymphoblastic Leukemia
Elias Jabbour, MD, MD Anderson Cancer Center
A panel of experts briefly reviews how both pediatric and adult patients with acute lymphoblastic leukemia (ALL) typically present and describes a standard patient workup.
EP. 2: Differentiating Subtypes of Acute Lymphoblastic Leukemia
Elias Jabbour, MD, MD Anderson Cancer Center
Elias Jabbour, MD, leads a discussion on the similarities and differences between ALL subtypes and their respective incidence rates.
EP. 3: Emergent Data Concerning Risk Factors for Acute Lymphoblastic Leukemia
Elias Jabbour, MD, MD Anderson Cancer Center
Armin Ghobadi, MD, and fellow panelists discuss new data concerning patients most at risk for developing ALL.
EP. 4: Standard Prognoses for Pediatric and Adult Patients with Acute Lymphoblastic Leukemia
Elias Jabbour, MD, MD Anderson Cancer Center
Ryan Cassaday, MD, notes differences between prognoses for patients with ALL based-on age, subtype, and disease progression status.
EP. 5: Assessing Minimal Residual Disease in Patients with Acute Lymphoblastic Leukemia
Elias Jabbour, MD, MD Anderson Cancer Center
Four clinicians share best practices for assessing minimal residual disease (MRD) for ALL, touching on how these practices are evolving over time.
Elias Jabbour, MD, MD Anderson Cancer Center
Gary J. Schiller, MD and fellow panelists discuss clinical trial outcomes presented at the ASH 2022 annual meeting relevant to patients with Philadelphia chromosome-positive ALL.
Elias Jabbour, MD, MD Anderson Cancer Center
The panelists review highly anticipated results from the E1910 trial assessing combination blinatumomab/consolidation chemotherapy in patients with Philadelphia chromosome-negative ALL.
EP. 10: CAR T-cell Therapy in Patients with R/R Acute Lymphoblastic Leukemia
Elias Jabbour, MD, MD Anderson Cancer Center
Dr Schiller summarizes results from the ZUMA-3 trial and poses thoughtful questions to fellow panelists regarding clinical significance.
EP. 11: Inotuzumab as an Option for Patients with R/R Acute Lymphoblastic Leukemia
Elias Jabbour, MD, MD Anderson Cancer Center
Dr Jabbour and fellow panelists share their thoughts on the benefits of Inotuzumab ozogamicin, particularly in a pre-allogeneic HSCT setting.
EP. 12: Applications for Blinatumomab in Treating Patients with R/R Acute Lymphoblastic Leukemia
Elias Jabbour, MD, MD Anderson Cancer Center
Dr Cassaday discusses data supporting the use of combination blinatumomab and pembrolizumab in patients with R/R ALL.
EP. 14: On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment Landscape
Elias Jabbour, MD, MD Anderson Cancer Center
Closing thoughts from a panel of ALL experts on improving access to therapy and how their field may evolve in years to come.
